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The recently discovered FabV enoyl-ACP reductase,
which catalyzes the last step of the bacterial fatty
acid biosynthesis (FAS-II) pathway, is a promising
but unexploited drug target against the reemerging
pathogen Yersinia pestis. The structure of Y. pestis
FabV in complex with its cofactor reveals that the
enzyme features the common architecture of the
short-chain dehydrogenase reductase superfamily,
but contains additional structural elements that are
mostly folded around the usually flexible substrate-
binding loop, thereby stabilizing it in a very tight
conformation that seals the active site. The struc-
tures of FabV in complex with NADH and two newly
developed 2-pyridone inhibitors provide insights for
the development of new lead compounds, and
suggest a mechanism by which the substrate-
binding loop opens to admit the inhibitor, a motion
that could also be coupled to the interaction of
FabV with the acyl-carrier protein substrate.
INTRODUCTION
Plague is among the most infamous ancient diseases, depopu-
lating medieval Europe in disastrous epidemics. The causative
agent is the Gram-negative bacterium Yersinia pestis, which
was first described by Alexandre Yersin during an outbreak of
plague in Hong Kong in 1894 (Burns, 2010). In the 20th century,
plague caused extensive deaths in India and Vietnam, and even
nowadays it remains a life-threatening disease in Africa, Asia,
and the Americas (Perry and Fetherston, 1997; Titball and Leary,
1998). Between 1992 and 2001, 28,956 caseswere reportedwith
2,064 deaths, of which about 84% occurred in Africa alone
(World Health Organization, 2004). If the disease is diagnosed
soon after infection, treatment with conventional antimicrobial
agents such as gentamycin, streptomycin, or doxycycline is
usually effective (Butler, 2009). However, in 1995, two highly
drug-resistant strains of Y. pestis were reported in Madagascar
(Galimand et al., 2006; Guiyoule et al., 1997, 2001). The continualStructure 20, 8reports of cases in endemic areas, as well as the evolution of
resistant strains, led to the classification of plague as a reemerg-
ing disease by the World Health Organization (Galimand et al.,
2006). The emergence of drug-resistant strains in Madagascar
(1995) and the possibility that this pathogen could be used as
a biological weapon (Richard and Grimes, 2008) underline the
danger arising from this neglected organism and hence the
need to identify new drug targets in the struggle against this
disease.
The bacterial fatty acid biosynthesis (FAS-II) pathway carries
an untapped potential for drug discovery (Lu and Tonge, 2008;
Wright and Reynolds, 2007). This pathway differs significantly
from the mammalian FAS-I pathway, which utilizes a multien-
zyme complex, in contrast to the discrete enzymes that sepa-
rately accomplish every step of the bacterial elongation cycle.
In the FAS-II pathway, the acyl-intermediates are shuttled
between the enzymes by the small, negatively charged acyl-
carrier protein (ACP). Some of the currently used antibacterial
agents have been shown to target the FAS-II pathway. Isoniazid,
one of the frontline drugs against tuberculosis, and triclosan,
a broad-spectrum antiseptic, both inhibit the last and rate-
limiting step of the FAS-II pathway (Heath et al., 1998; Que´mard
et al., 1995). In this last step, the double bond of the enoyl-ACP is
reduced in an NAD(P)H-dependent step to acyl-ACP by an
enoyl-ACP reductase. Currently, four enoyl-ACP reductase
isoenzymes are known: FabI, FabL, and FabV, which belong to
the short-chain dehydrogenase/reductase superfamily (SDR),
and FabK, a flavoprotein, which uses the flavin cofactor
FMNH2 to reduce the enoyl double bond (Marrakchi et al.,
2003; Massengo-Tiasse´ and Cronan, 2009). The recently identi-
fied isoform FabV (Massengo-Tiasse´ and Cronan, 2008) is the
only known isoenzyme in Vibrio cholerae and Y. pestis, and is
present along with FabI in Pseudomonas aeruginosa and
Burkholderia mallei (Lu and Tonge, 2010; Massengo-Tiasse´
and Cronan, 2009; Zhu et al., 2010). FabV differs from the previ-
ously characterized SDR enoyl-ACP reductases in various
aspects. With 400 residues, it is about 60% larger than the
established SDR-family members FabI and FabL, and the overall
sequence identity with these isoenzymes is limited to 15%. In
contrast to the other SDR enoyl-ACP reductases, which contain
the Y-(Xaa)6-K active site consensus sequence, the FabV active
site residues are separated by two additional amino acids9–100, January 11, 2012 ª2012 Elsevier Ltd All rights reserved 89
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However, a detailed kinetic analysis of B. mallei FabV (bmFabV)
revealed that it follows a sequential bi-bi mechanism, with NADH
binding first and NAD+ dissociating last, which is similar to the
mechanism observed for other FabIs (Lu and Tonge, 2010).
Nevertheless, inhibition of the enoyl-ACP reductases reveals
differences among these enzymes. Whereas triclosan is
a slow-onset nM to pM inhibitor of all studied FabIs apart from
that from Mycobacterium tuberculosis, the flavoprotein FabK is
triclosan resistant, and FabL does not form a stable ternary
complex with NAD+ and triclosan (Heath et al., 2000). Likewise,
triclosan is a rapid reversible inhibitor of bmFabV with a Ki of
0.4 mM (Lu and Tonge, 2010), and for P. aeruginosa, a pathogen
that contains both FabI and FabV, it was shown that FabV medi-
ates triclosan resistance (Zhu et al., 2010). Consequently, in
order to interfere with the bacterial fatty acid biosynthesis
pathway in severe Gram-negative pathogens that contain the
FabV enoyl-ACP reductase, such as Y. pestis, P. aeruginosa,
or V. cholerae, new potent inhibitors of FabV are needed. Here,
we present the structure of FabV from Y. pestis in the presence
of its cofactor NADH and in complex with, to our knowledge,
two novel 2-pyridone inhibitors that advance our understanding
of this very distinct enoyl-ACP reductase isoform. These struc-
tures provide intriguing insights into the mechanism of substrate
recognition and will aid in the development of novel inhibitors
against this reemerging pathogen.
RESULTS AND DISCUSSION
Overall Structure of FabV in Comparison to FabI
The structure of Y. pestis FabV (ypFabV) was solved by X-ray
crystallography using single isomorphous replacement with
anomalous scattering (SIRAS) from a crystal soaked in 300 mM
NaI (Table 1). The structure revealed that the His tag and the
following linker region lead to the formation of a dimer in the
crystal (see Figure S1 available online). To exclude the influence
of these additional residues on the overall protein structure, part
of the linker and His tag were removed by thrombin cleavage.
The cleaved protein crystallized in space group P3121, with
one molecule in the asymmetric unit. The structure was solved
by molecular replacement using the model of the His-tagged
structure as a search model, and was refined to R factors of
16.8% and 21.2% (Rfree). The resulting model contains all 405
residues.
Recently it was shown that FabV from V. cholerae forms
a monomer in solution (Massengo-Tiasse´ and Cronan, 2008).
The crystal form of ypFabV analyzed in this study also indicates
a monomer as the biological assembly. This result is quite
surprising, because the well-characterized FabI and FabL
enoyl-ACP reductases of this family form tetramers, and the
SDR superfamily in general consists of dimers or tetramers.
Despite its significantly increased size, the core of FabV shows
the typical structure of an SDR family member (Figures 1A and
1C). Most of the N-terminal part of the protein forms a Rossmann
fold, with an eight-stranded parallel b sheet surrounded by three
and four a helices on either side. The Rossmann fold (Buehner
et al., 1973) provides the cofactor binding site, whereas the
C-terminal part of the protein, which is usually smaller in the
SDR family, forms the catalytic site and generates substrate90 Structure 20, 89–100, January 11, 2012 ª2012 Elsevier Ltd All righspecificity. Additional insights into the properties of the protein
arise from the comparison of the FabV structure with the struc-
ture of its related isoenzyme FabI. In the structural comparison
search against the Protein Data Bank (PDB) using secondary
structure matching (SSM) (Krissinel and Henrick, 2004), the
protein structures with the highest structural similarity were
FabI from Escherichia coli (ecFabI) in a ternary complex with
NAD+ and different inhibitors such as triclosan (ecFabITCL; PDB
ID codes 1C14, 1QG6, and 1QSG; Qiu et al., 1999; Stewart
et al., 1999; Ward et al., 1999) (Figures 1B–1D). Although ypFabV
shares only 17% sequence identity with ecFabI (Figure 2), the
three-dimensional structures are significantly more similar, and
50% of the secondary structure elements of ypFabV overlap
with the ecFabITCL structure according to SSM analysis (using
PDBeFold; Krissinel and Henrick, 2004). A detailed comparison
between the FabI and FabV structures is presented in Supple-
mental Information. YpFabV is140 residues larger than ecFabI,
and the majority of these additional residues are located in and
around the ypFabV active site. An extended b hairpin (b9/b10)
lies on top of the active site and covers, together with an
N-terminal b hairpin (b1/b2), the substrate-binding loop and
the following helix (a9), which interacts with ACP in FabI (a8).
Four additional helices (a11, a12, a13, a14) surround this
central part of the enzyme, thereby stabilizing the substrate-
binding pocket of FabV. These additional secondary structure
elements may stabilize the protein sufficiently, and thus further
stabilization by oligomerization into dimers or tetramers, as
observed for the usually smaller SDR superfamily members, is
not required.
The major difference between apo-FabI and its inhibitor-
bound structure is the substrate-binding loop. In the apo or
cofactor-bound FabI structures, the substrate-binding loop
is flexible and therefore not observed in the structure. However,
in the inhibitor-bound complex, the substrate-binding loop is
defined and stabilized by the inhibitor. In contrast to FabI, the
conformation of the substrate-binding loop in FabV is already
well defined in the presence of the cofactor, and does not
require further stabilization by either a substrate or an inhibitor.
Superposition of FabV with the recently published FabL struc-
tures from Bacillus subtilis in the presence (PDB ID code
3OID) and absence (PDB ID code 3OIC) of triclosan (Kim et al.,
2011) reveal even more pronounced differences. The ternary
FabL complex displays a structure comparable to that of the
cofactor-bound FabV complex (Figure 1B); in the FabL apo
structure, however, not only the substrate-binding loop (h5 in
ecFabITCL) but also the helix carrying the catalytic residues is
disordered.
Cofactor Binding
The Rossmann fold is the conserved feature of all members of
the diverse SDR superfamily, which share low sequence identity
and can be classified into five subfamilies (classical, extended,
intermediate, divergent, and complex SDRs) according to their
cofactor binding and active site motifs (Kallberg et al., 2002;
Kavanagh et al., 2008; Oppermann et al., 2003). FabI and FabL
are members of the ‘‘divergent’’ subfamily, with a cofactor
binding motif consisting of GxxxxxSxA. This motif is partially
conserved in ypFabV, although the conserved serine is replaced
by a glycine (marked by a box in Figure 2). The NADH cofactor ists reserved
Table 1. Data Collection and Refinement Statistics
Iodine SIRAS Native SIRAS Cleaved His Tag MR PT172 MR PT173 MR
Data Collection
Wavelength (A˚) 1.25 0.918 0.918 1.54 1.54
Space group P6522 P6522 P3121 P3121 P3121
Unit cell parameters
a/b/c (A˚) 103.8/103.8/220.2 104.2/104.2/219.1 102.2/102.2/86.8 101.7/101.7/84.6 101.7/101.7/84.6
a/b/g 90/90/120 90/90/120 90/90/120 90/90/120 90/90/120
Resolution (A˚) 89.9–3.1 39.4–2.1 33.4–1.80 44.1–2.0 42.2–2.0
Total reflections 455,984 344,333 352,957 151,845 202,752
Unique reflections 13,483 48,035 47,522 34,293 34,559
Completeness (%) 100 (100) 99.8 (100) 100 (100) 100 (100) 100 (100)
Redundancy 33.8 (35.3) 7.2 (7.3) 7.4 (7.4) 4.4 (4.3) 5.9 (5.7)
Anomalous completeness 100
Anomalous redundancy 18.8
Rmerge (%)
a 11 (93) 6 (62) 10.6 (63) 6.6 (46) 7.6 (54)
<I/s(I)> 26.9 (5.4) 15.8 (3) 13.2 (3.3) 14.2 (3.0) 13.1 (2.5)
Phasing
Iodide per asymmetric unit 15
Phasing power
(centric/acentric/anomalous)
0.948/1.000/0.692
Figure of merit (after phasing)
(centric/acentric)
0.12751/0.09256
Figure of merit after density modification 0.598
Refinement
Total number of atoms 3,399 3,777 3,605 3,569
Rcryst (%)
b 19.9 16.8 17.6 18.8
Rfree (%)
c 22.8 21.2 22.1 22.8
Rmsd from ideal
Bond length (A˚) 0.007 0.007 0.014 0.015
Bond angles () 1.14 1.07 1.48 1.51
Average B values (A˚2 and number of atoms)
All atoms (3,399) 72.8 (3,777) 26.0 (3,605) 26.7 (3,570) 31.8
Protein (3,195) 74.7 (3,284) 24.4 (3,303) 25.9 (3,288) 31.0
NADH (44) 54.2 (44) 16.5 (44) 31.2 (44) 36.2
Water (160) 60.7 (425) 38.0 (237) 34.0 (215) 39.4
Glycerin (24) 50.8
Inhibitor (21) 48.2 (22) 55.5
Na (1) 58.3 (1) 22.8 (1) 40.1 (1) 50.0
Ramachandran plot (MolProbityd)
Most favored (%) 96.2 97.5 97.3 97.3
Allowed (%) 3.6 2.5 2.7 2.7
Disallowed 0.2 0 0 0
PDB ID code 3zu2 3zu3 3zu4 3zu5
Values in parentheses are for the highest-resolution shell. MR, molecular replacement.
a Rmerge =
P
hkl
P
ijIi  hIij=
P
hkl
P
ihIi, where Ii is the ith measurement and hIi is the weighted mean of all measurements of I.
bRcryst =
PjjFoj  jFcjj=P jFoj, where Fo and Fc are the observed and calculated structure factor amplitudes, respectively.
c Rfree same as Rcryst for 5% of the data randomly omitted from refinement.
dChen et al., 2010.
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Structural Characterization of FabV from Y. pestisbound in a tight network of hydrogen bonds involving fixed
solvent molecules (Figure 3). Most residues of the glycine-rich
conserved motif (G48–G58) are involved in NADH binding andStructure 20, 8form several hydrogen bonds to the cofactor. The active site
residue K244 forms hydrogen bonds to both hydroxyl residues
of the nicotinamide ribose, whereas Y235 interacts via a water9–100, January 11, 2012 ª2012 Elsevier Ltd All rights reserved 91
Figure 1. Overall Structure of ypFabV in Comparison to Known Isoenzymes of the SDR Family
(A) The FabV structure is shown as a ribbon diagram with helices (h = 310helix) in red and b strands in yellow.
(B) The ypFabV structure (cyan) is superimposed with ecFabITCL (PDB ID code 1C14) (magenta) and B. subtilis FabLTCL (PDB ID code 3OID) (blue), both in the
triclosan-bound state. Two orientations are shown, with the substrate-binding loop marked as helix a8.
(C and D) Topology diagrams of ypFabV and ecFabITCL. Similar structural elements are shown in cyan, and differing elements in yellow.
See also Figure S1 and Supplemental Information.
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Structural Characterization of FabV from Y. pestismolecule with one of the hydroxyl groups. A detailed description
of all the interactions formed between the cofactor and the
protein can be found in Supplemental Information. Because
FabV shares only parts of the sequence motif for cofactor
binding, this subfamily-defining motif has to be revised if FabV
should belong to the subfamily of divergent SDRs.
The Active Site
The second, most critical motif for subfamily assignment is the
active site motif. For the divergent subfamily, a consensus
sequence of YxxMxxxK was described in which the tyrosine
and the lysine residues play a direct role in catalysis (Kavanagh
et al., 2008). In FabV, the active site residues are separated by
two additional amino acids and are missing the conserved
methionine, which is replaced by isoleucine leading to an active
site motif of Y(x)8K. Despite this insertion, the position of the two
active site residues Y235 and K244 in the catalytic center of
the enzyme is structurally conserved in comparison to Y156
and K163 of ecFabITCL (Figure 4A). Y235 is thought to bind the
thioester carbonyl oxygen, thereby stabilizing the transition state92 Structure 20, 89–100, January 11, 2012 ª2012 Elsevier Ltd All righfor substrate reduction. In addition, the second active site tyro-
sine residue in FabI (Y146) is also structurally conserved in
ypFabV (Y225). Adjacent to the known active site lysine (K244),
which is thought to interact with the cofactor as well as with
the acyl substrate, an additional lysine (K245) is present. Inter-
estingly, this second lysine is conserved in FabV from different
organisms. It was shown for bmFabV that the mutation of this
lysine to methionine (K245M) did not impair NADH binding, but
increased the Km value for trans-2-dodecenoyl-CoA about
10-fold (Lu and Tonge, 2010). However, in the cofactor-bound
ypFabV structure, the side chain of K245 points away from the
binding pocket. In order for K245 to interact directly with the
substrate, the helix that carries both lysine residues has to rotate.
This is highly unlikely because the active site lysine K244 would
thenmove out of its cofactor-binding position. Instead of binding
the substrate directly, K245 forms hydrogen bonds to the back-
bone carbonyl of W236 and the side-chain oxygen of N237, and
in this way connects the loop that carries the active site tyrosine
(Y235) to helix a7, which carries the catalytic lysine (K244) (Fig-
ure 4B). Thus, it is highly probable that K245 holds the catalyticts reserved
Figure 2. Sequence Alignment of ypFabV and ecFabI
Sequence alignment (CLUSTAL W; Thompson et al., 1994) of ypFabV and ecFabI, with the cofactor binding motif shown in a blue box. Conserved active site
residues are marked by blue asterisks. Secondary structure elements are indicated by arrows and spirals for b strands and a helices, respectively and shown
above (ypFabV) and below (ecFabI) the sequence. 310helixes are labeledwith h and b turns with TT. The conserved residues are highlighted in the blue boxes, with
the most conserved residues colored in white with a red background.
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Structural Characterization of FabV from Y. pestisresidues in the correct orientation, and thereby has an indirect
effect on substrate binding.
The Substrate-Binding Loop
A surprising finding of the cofactor-bound structure is the well-
defined substrate-binding loop (helix a8, residues S276–
M284), which is ordered despite the absence of either a bound
inhibitor or substrate. The substrate-binding loop displays the
same helical fold as in the ecFabITCL structure, and seems to
close the binding pocket, constricting both the entrance and
volume of the active site pocket relative to FabI. In the ternary
FabI complexes, the helical substrate-binding loop has to be
stabilized by hydrophobic interactions with a bound inhibitor or
substrate. In contrast, the substrate-binding loop in FabV is
stabilized by interactions with the cofactor and some of the addi-
tional structural elements (Figure 4C). The N-terminal portion
of the substrate-binding loop is embedded in a network of
hydrogen bonds, arising mainly from the Rossmann fold and
the cofactor. Q277 is involved in a hydrogen-bonding network
via four water molecules, connecting it to the NADH adenosine
phosphate moiety and residues T51, E75, S86, G87, N90, and
L373. On the N-terminal b hairpin (b1/b2), F10 forms hydrogenStructure 20, 8bonds to S276 and S280, thereby stabilizing the central part of
the substrate-binding loop again via a water bridge. These polar
interactions are supported by hydrophobic interactions, mostly
located at the other end of the substrate-binding loop involving
A140/L157 (before/after the b8/9 hairpin), L181 (b10), I230/I234
(h1, next to the active site), W349 (a12), and F370/F374 (a14).
The hydrophobic pocket that surrounds the C-terminal portion
of the substrate-binding loop is complemented by additional
structural elements such as a b hairpin (b9/b10), which closes
the binding pocket. Thus, the binding pocket of FabV is quite
tightly closed and rigid, in contrast to the flexible, open binding
site observed in binary FabI complexes. Although our binary
complex of ypFabV contains NADH, in contrast to the binary
complex structures of bacterial FabIs that all contain NAD+, there
is no distinct interaction between NADH and the substrate-
binding loop, which could not also be mediated by NAD+. The
closed conformation of the substrate-binding loop in the binary
complex can thus not be explained by the fact that it is
a substrate complex instead of a product complex, as in the
binary FabI structures. Despite these differences between FabI
and FabV, the architecture of the active site is remarkably
conserved.9–100, January 11, 2012 ª2012 Elsevier Ltd All rights reserved 93
Figure 3. The Cofactor Binding Site Is Structurally Conserved
(A) The cofactor NADH (yellow) is shown with its SIGMAA-weighted 2Fo  Fc electron density omit map (s = 1.5); the protein is shown in ribbon presentation.
(B) Stereo view of cofactor binding. The cofactor NADH (yellow) is bound through a variety of hydrogen bonds (dashed lines) partially connected by water
molecules (red spheres) and a sodium ion (violet sphere) as well as through hydrophobic interactions.
See also Supplemental Information.
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The low affinity of the FabI inhibitor triclosan for FabV is another
interesting aspect of this newly discovered enoyl-ACP reduc-
tase. Triclosan (Figure 5A) is a slow-onset inhibitor of ecFabI
(Ki = 7 pM) (Lu and Tonge, 2008; Sivaraman et al., 2004), and it
has been hypothesized that during the slow step of the binding
process the flexible substrate-binding loop forms hydrophobicFigure 4. The Substrate-Binding Loop and the Active Site
(A) The active site residues and the cofactor of ypFabV (cyan) and FabI (violet) a
(B) The conserved residue K245 interacts with N237 andW236 and thereby stabiliz
other (helices a7 to h1). A water molecule interacts with Y235 in place of the sub
(C) The substrate-binding loop (yellow) is stabilized by van der Waals interact
interactions arise from the additional secondary structure elements such as a12,
94 Structure 20, 89–100, January 11, 2012 ª2012 Elsevier Ltd All righinteractions with the inhibitor, resulting in a defined helical
conformation (Qiu et al., 1999). Because the substrate-binding
loop is already ordered in ypFabV and its conformation is very
similar to that of the triclosan-bound ecFabI structure, one might
expect that triclosan would also bindwith high affinity to ypFabV.
However, in previous studies (Lu and Tonge, 2010), it was shown
that triclosan is a rapid reversible inhibitor of bmFabV, with a Kire superimposed and shown in all-bonds representation.
es the position of the active site residues Y235 andK244 (violet) relative to each
strate.
ions (violet residues) and hydrogen bonds (cyan residues). Many stabilizing
a14, b7, b8, and b10.
ts reserved
Figure 5. Inhibition of ypFabV
(A) Chemical structure of the inhibitors triclosan, PT70, PT172, and PT173.
(B) The inhibition of ypFabV in the presence of 50 mM (C), 100 mM (,), or 200 mM triclosan (-) and in the absence of inhibitor (B).
(C) The inhibition of ypFabV in the presence of 1 mM (C), 2 mM PT172 (,), or 4 mM PT172 (-) and in the absence of inhibitor (B).
(D) The inhibition of ypFabV in the presence of 0.5 mM (C), 1 mM (,), or 2.5 mM PT173 (-) and in the absence of inhibitor (B).
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Structural Characterization of FabV from Y. pestisvalue of only 0.4 mM.Here we show that triclosan binds with even
lower affinity to ypFabV with a K0 i value of 71 ± 4 mM, which is
100 times less than the corresponding value for bmFabV
(Figure 5B).
Structure-activity relationship studies based on the diphenyl
ether scaffold of triclosan have resulted in a number of potent
inhibitors of the FabI enzyme from pathogens such as
Staphylococcus aureus (saFabI), M. tuberculosis, and Plasmo-
dium falciparum (am Ende et al., 2008; Chhibber et al., 2006;
Lu and Tonge, 2008; Sullivan et al., 2006). One such compound
is PT70 (Figure 5A), which is a slow-onset inhibitor of the
M. tuberculosis FabI (InhA) (Luckner et al., 2010). However,
despite their ability to potently inhibit FabI, the diphenyl ethers
are susceptible to phase II conjugation reactions, and we are
currently exploring the utility of replacing the diphenyl ether A
ring with a 2-pyridone, which has been identified as a promising
scaffold for the inhibition of saFabI (Tipparaju et al., 2008, 2010;
Yum et al., 2007). In the present study, the A ring of our 2-pyri-
done inhibitors is substituted with a C6 alkyl chain to mimic the
ypFabV substrate, whereas the B ring carries either an ortho
chlorine substituent (PT172) or an ortho methyl group together
with a meta amine (PT173) (Figure 5A). Interestingly, PT172Structure 20, 8(Figure 5C) and PT173 (Figure 5D) are competitive inhibitors of
ypFabV, with Ki values of 2.1 ± 0.4 mM and 1.5 ± 0.3 mM,
respectively.
To characterize the interactions of these promising 2-pyridone
inhibitors with ypFabV and to gain more insight into their molec-
ular effect on ypFabV, both inhibitors were cocrystallized with
the protein in the presence of the cofactor. The protein portion
of the two ternary complexes is almost identical to each other,
with a root-mean-square deviation (rmsd) of 0.09 A˚ (all atoms).
Both structures can be superimposed with the cofactor-bound
ypFabV structure (rmsd = 0.2 A˚, all atoms) with one notable
exception (Figure 6). The substrate-binding loop, together with
the b turn of the N-terminal b hairpin (b1/b2), is shifted by 3 A˚
out of the active site pocket. The binding pocket is thereby
broadened, which allows the inhibitor entrance to the pocket
and provides sufficient space for binding. This shift of the
substrate-binding loop indicates a completely reversed inhibitor
binding behavior of ypFabV compared to FabI. FabV has to
loosen its tight conformation to provide space for the inhibitor.
Furthermore, in contrast to FabI, the substrate-binding loop
does not contribute to the hydrophobic interactions with the
inhibitor. The distance between the substrate-binding loop andFigure 6. The Substrate-Binding Loop
Shifts upon Inhibitor Binding
(A) The binary FabV-NADH structure (cyan/yellow)
is superimposed onto the ternary FabV-PT173-
NADH (carbon atoms of the ligands are shown
in black/grey) complex structure (dark violet/red).
Differing parts of the FabV structure are high-
lighted in yellow and red. The substrate-binding
loop is shifted away from the active site together
with the N-terminal b hairpin in the inhibitor
structures.
(B) Zoom into the active site.
9–100, January 11, 2012 ª2012 Elsevier Ltd All rights reserved 95
Figure 7. Inhibitor Binding
(A) PT172 (magenta sticks) forms hydrogen bonds (dashed lines) to FabV and parallel displaced p-p stacking interactions to the nicotinamide ring of NADH.
The substrate loop is shown in yellow.
(B) The conformation of the bound inhibitors PT172 (magenta) and PT173 (black) differs in a rotation of the B ring by 24.
(C) Residues of FabV interacting with PT172 via hydrogen bonds or through van der Waals interactions are shown in all-bonds representation, with hydrogen
bonds as dashed lines.
(D) Residues of FabV interacting with PT173 via hydrogen bonds or through van der Waals interactions are shown in all-bonds representation, with hydrogen
bonds as dashed lines.
See also Supplemental Information and Figure S2.
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Instead, water molecules between polar residues such as S276
and S279 and the inhibitor mediate interactions between the
cofactor and the substrate-binding loop (Figure 7A).
Apart from this intriguing difference, the enzyme-inhibitor
interactions in the ypFabV structures closely resemble those
observed in FabI-triclosan structures (Figure 7A) (Qiu et al.,
1999; Sivaraman et al., 2003, 2004; Stewart et al., 1999). The
carbonyl oxygen in the pyridone ring forms a hydrogen bond to
the hydroxyl group of Y235 as well as to the nicotinamide ribose.
In addition, the parallel-displaced p-p stacking interaction
between the A ring and the nicotinamide ring of the cofactor is
also present. The position of the A ring is identical in both inhib-
itor structures, whereas the carbon chain and the B ring show
a slightly different conformation (Figure 7B). The hexyl chain is
flexible, which is reflected in a more diffuse electron density.
The B ring, on the other hand, is well defined in the density but
is tilted by 24. The B ring and the hexyl chain of the PT172 inhib-
itor form hydrophobic interactions to residues A140, M196,96 Structure 20, 89–100, January 11, 2012 ª2012 Elsevier Ltd All righY225, T231, A273, and M285 (Figure 7C). In PT173, the amine
group on the B ring forms hydrogen bonds via a water bridge
to the side chain of S155 and the carboxyl oxygen of S141 (Fig-
ure 7D). This causes the B ring to move toward the water mole-
cule, which leads to the loss of the hydrophobic interaction with
M196.
To determine the reason for the decreased affinity of triclosan
compared to the new 2-pyridone inhibitors, docking trials were
performed using the ternary complex form of ypFabV. The dock-
ing results suggest that triclosan is unlikely to adopt the binding
mode in ypFabV that is observed in other enoyl-ACP reductases.
Instead, appropriate positioning of the diphenyl ether skeleton in
the active site was only obtained when docking was carried out
for a triclosan derivative in which the chloro substituent of the A
ring was replaced by an n-hexyl chain, as in PT172 and PT173.
This finding underlines the importance of the hexyl chain for
ypFabV inhibition. A detailed description of the triclosan docking
approach can be found in Supplemental Information and
Figure S2. Although the structural data demonstrate how thets reserved
Figure 8. Substrate-Binding Channels
(A) Potential entry channels (calculated with CAVER) of the binary FabV-NADH
complex structure through the minor (left) and major portals (right) are shown
as gray clouds.
(B) The channel through the major portal is broader than through the minor
portal. Close to the channel entrance three basic residues, K4, R6, and R8
(blue), could potentially interact with ACP. The enoyl substrate could be
accommodated in the hydrophobic patch (shown in light orange) next to the
basic residues.
(C) Hypothetical substrate-binding mode: the PT173 complex structure is
colored according to its temperature factors (red, high; blue, low). The basic
residues K4, R6, and R8 are shown as sticks next to the major portal. The
cofactor is shown as sticks. ACPmight interact through its acidic residues with
the basic residues of the N-terminal b hairpin, thereby moving the substrate-
binding loop (red) out of the pocket and opening the major portal for the
substrate.
Structure
Structural Characterization of FabV from Y. pestis2-pyridone inhibitors interact productively with ypFabV, further
studies are required to determine why the 2-pyridones are
preferred over the diphenyl ether scaffold.
Potential Substrate Entry to the Binding Pocket
Even though the binding pocket and the active site of FabV
share similarities to FabI, the additional structural elements
occlude the active site pocket from the surrounding solvent,
and thus pose the question of how substrates reach their desti-
nation. An additional criterion for a possible substrate channel is
the availability of a potential ACP interaction site. In general,
negatively charged residues located on helix aII of ACP interact
with hydrophobic and electropositive surfaces on the target
proteins, which include lysine and arginine residues. ACP is
thereby capable of interacting with a variety of different
enzymes, yet it binds only with low affinities (low mM range) to
the target proteins (Chan and Vogel, 2010; Parris et al., 2000;
Rafi et al., 2006; Zhang et al., 2003a, 2003b). In FabV, the
basic residues, which presumably interact with ACP, are not
conserved, and the helix, which seems to be responsible for
ACP binding in FabI, is covered by two b hairpin structures in
ypFabV.
For FabI, two main entry sites to the active site pocket have
been termed the minor and the major portals, with the latter
being much wider (Rozwarski et al., 1999). Nevertheless, in the
ecFabI-ACP complex structure (Rafi et al., 2006), the acyl-pante-
theine adduct was modeled by molecular dynamics simulations
through the minor portal. For the cofactor-bound structure of
ypFabV, molecular channels leading from both entry sites could
be verified in MOLE and CAVER (Petrek et al., 2006, 2007) (Fig-
ure 8A). However, the channel through the minor portal in FabV
is very narrow because of the tightly closed conformation of
the substrate-binding loop and the long b hairpin (b9/b10)
covering the binding pocket. The other possibility is an entry of
the substrate through the major portal. In a substrate analog
complex structure of InhA, the N-acetyl cysteamine portion of
the C16 fatty acid substrate, which would be physiologically
coupled to ACP, faces the major portal (Rozwarski et al.,
1999). Next to the major portal in FabV, the N-terminal b hairpin
(b1/b2) spreads out with three very prominent basic residues, K4,
R6, and R8, on b1 and a stretch of hydrophobic residues (G9,
F10, I11, V13, and A15) on b turn (b1/b2) and b2 (Figure 8B).
ACP could bind to these basic residues and present the
substrate to the hydrophobic patch that leads into the binding
pocket. This scenario is supported by the inhibitor structures,
if it is assumed that the alkyl substituents mirror the interaction
of substrates with the enzyme. Thus, a comparable outward
movement of the substrate-binding loop, as observed in the
inhibitor-bound structures, will probably also occur upon
substrate binding. Apart from the substrate-binding loop, only
the N-terminal b hairpin (b1/b2) moves upon inhibitor binding,
underlining its strong connection to the substrate-binding loop.
Furthermore, this movement only broadens the major portal,
whereas the minor portal remains narrow. One could thus spec-
ulate that the b1/b2 hairpin, containing the three basic residues,
is pulled away from the active site upon ACP binding (Figure 8C).
The substrate-binding loop, to which the b1/b2 hairpin is con-
nected, follows this outward movement and opens the active
site for the enoyl substrate, which can then easily enter the activeStructure 20, 8site via the hydrophobic patch, located adjacent to the putative
ACP binding site.
Conclusions
The structure of ypFabV confirms the unique character of this
SDR enoyl-ACP reductase. YpFabV is 140 residues larger
than the typical FabI isoforms, and these additional residues
are mainly located around the substrate-binding loop. This
usually flexible loop is central for the function of FabI, because
it enables the enzyme to adapt to substrates of various sizes
and is only closed when ligands are bound. In contrast, FabV
seems to follow an inverse mechanism. Without a substrate
bound, it adopts a closed conformation that has to open to allow
access of the enoyl substrate or an inhibitor, as observed in the9–100, January 11, 2012 ª2012 Elsevier Ltd All rights reserved 97
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Structural Characterization of FabV from Y. pestisPT172 and PT173 complex structures. Thesemechanistic differ-
ences might lead to different requirements for the inhibition of
each enzyme. In addition, the pyridone inhibitors characterized
in this study reveal that FabV can be targeted by a structure-
based drug design approach, and holds the promise that
inhibitors can be identified that target both FabI and FabV
simultaneously.EXPERIMENTAL PROCEDURES
Cloning, Expression, and Purification of ypFabV
The fabV gene was amplified from the Y. pestisCO92 genome (NCBI reference
sequence YP_002348955.1, with a mutation at position 276 in the polypeptide
yielding the ypFabV variant T276S) using the following primers (Integrated DNA
Technologies): 50-CCGCTCGAGATGATTATAAAACCACGTGATA-30 (forward)
and 50-CCGGAATTCTTAACCCTGAATCAAGTTAGG-30 (reverse). The PCR
product was digestedwith XhoI and EcoRI and inserted into the pET15b vector
(Novagen), adding a His tag at the N terminus. The target sequence was
confirmed by sequencing.
Protein expression and purification were performed as described previously
using E. coli BL21(DE3) pLysS cells (Xu et al., 2008).
To remove the N-terminal His tag, 1 ml of biotinylated thrombin was added to
1 ml of ypFabV (20 mM) in PIPES buffer. The reaction mixture was incubated at
room temperature for 16 hr. Streptavidin agarose (20 ml) was added, and the
solution was incubated for an additional hour, after which the agarose was
removed by centrifugation at 13,000 rpm for 10 min. The supernatant was
further purified by chromatography on a Sephadex G-25 column using PIPES
buffer as the eluent, and fractions containing ypFabV lacking the His tag were
pooled and analyzed via 12% SDS-PAGE.
Synthesis of trans-2-Dodecenoyl-CoA
trans-2-dodecenoyl-CoA (DD-CoA) was synthesized from trans-2-dodecenoic
acid using the mixed-anhydride method (Parikh et al., 2000). ESI-MS ([M-H])
gave a mass of 946.2 Da for DD-CoA, in perfect agreement with the mass of
946.2 Da calculated for [C33H53N7O17 P3S]
.
Steady-State Kinetics
All kinetic experiments were performed on a Cary 300 Bio (Varian) spectrom-
eter at 25C in 30mMPIPES buffer (pH 6.8) containing 150mMNaCl and 1mM
EDTA. Initial velocities were measured by monitoring the oxidation of NADH to
NAD+ at 340 nm (ε = 6,300 M1 cm1).
The inhibition mechanism was characterized by measuring initial velocities
at a fixed concentration of NADH (250 mM) and at various concentrations of
DD-CoA and inhibitor. Data were analyzed in Lineweaver-Burk plots. The
dissociation constant was calculated by fitting the data to Equations 1 and
2, which describe uncompetitive and competitive inhibition, respectively:
1
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=
Km
vmax

1
½S

+
1
vmax

1+
½I
K0i

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
+
1
vmax
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In Equations 1 and 2, [S] is the concentration of DD-CoA, [I] is the concen-
tration of inhibitor, Km is the Michaelis-Menten constant for DD-CoA, Vmax is
the maximum velocity, and Ki and K
0
i are the inhibition constants.
Protein Purification for Crystallization
For purification of ypFabV, the cells were thawed, resuspended, and lysed in
50 mMNa3PO4 (pH 7.4), 300 mM NaCl, and 5 mM imidazole. The soluble frac-
tion of the cell lysate was loaded on an Ni-TED (Protino) affinity column,
washed with 10 mM imidazole in the same buffer, and eluted with 250 mM
imidazole. The protein was further purified by size-exclusion chromatography
(Superdex 200 26/60; GE Healthcare/A¨KTA) using 20 mM PIPES (pH 7.6),
300 mM KCl, and 1 mM EDTA as the eluent. The protein sample was concen-
trated to 68 mg/ml, flash-frozen in liquid nitrogen, and stored at 80C.98 Structure 20, 89–100, January 11, 2012 ª2012 Elsevier Ltd All righThrombin Cleavage for Crystallization
Thrombin cleavage was integrated into the purification protocol after affinity
chromatography. The eluate of the Ni-TED column was concentrated up to
65 mg/ml and cleaved with 1 U thrombin (GE Healthcare)/mg protein at
room temperature overnight. The protease was removed via a benzamidine
column, and cleaved protein was purified by size-exclusion chromatography.
Crystallization and Data Collection
The protein sample (68 mg/ml) was preincubated with the cofactor NADH
(5-fold molar excess) for 30 min. One-microliter drops were equilibrated in
hanging-drop vapor-diffusion experiments at 20C against 1ml of the reservoir
solution containing 1.25–1.5 M sodium malonate and 100 mM buffer (citrate
[pH 5.6], imidazole [pH 8.25]). Crystals grew in space group P6522 with cell
parameters of a = b = 104 A˚, c = 220 A˚. For the SIRAS approach, crystals
were soaked with 300 mM NaI in the reservoir solution including 30% glycerol
as cryoprotectant for 10–30 s. A data set of the iodide-soaked crystals was
collected at beamline ID29 (European Synchrotron Radiation Facility [ESRF],
Grenoble) at a wavelength of 1.25 A˚, and a native data set was obtained at
beamline MX 14.1 (BESSY, Berlin). The cleaved FabV was treated likewise
and crystallized in 150 mM (NH4)2SO4, 25% polyethyleneglycol 4000, and
100 mM MES (pH 5.5). The diffraction data set was collected at beamline
MX 14.1 (BESSY).
Cocrystallization
For cocrystallization experiments, thrombin-cleaved FabV was preincubated
with the cofactor NADH (5-fold excess) and the inhibitor (5 mg/ml) for 2 hr.
The inhibitor complexes crystallized in 150 mM (NH4)2SO4, 35%–37% polye-
thyleneglycol 4000, and 100 mM MES (pH 5.5). Data were collected on
a Rigaku MicroMaxTM-007HF X-ray generator with a Raxis HTC detector
from cryopreserved crystals.
Structure Determination and Refinement
The data sets were indexed and integrated with iMosflm (Leslie, 1992) and
scaled in Scala (CCP4, 1994; Evans, 2006). Phasing of the tagged FabV crystal
was achieved by using the program autoSHARP (Vonrhein et al., 2007) in
a SIRAS approach. An initial model covering 88% of the ypFabV sequence
was automatically built by ARP/wARP (Langer et al., 2008), and the model
was subsequently revised and extended manually in Coot (Emsley and
Cowtan, 2004). For refinement in REFMAC and PHENIX (Adams et al.,
2010), TLS parameters were created using the TLSMD server (Painter and
Merritt, 2006), and a library file supplying restraints for the NADH cofactor
was created with the PRODRG server (Schu¨ttelkopf and van Aalten, 2004).
The tagged ypFabV structure was refined and validated using PHENIX (Adams
et al., 2010) and PROCHECK (in PDBsum; Laskowski, 2009). The structure of
the cleaved ypFabV was solved by molecular replacement using Phaser
(McCoy et al., 2007) with the structure of the tagged FabV as a search model.
Refinement and validation were performed as in the tagged protein. Interac-
tions were analyzed with the help of LIGPLOT (Wallace et al., 1995). Images
were created using the programs PyMOL (http://www.pymol.org), ESPript
(Gouet et al., 2003), TopDraw (Bond, 2003), and CAVER and MOLE (Petrek
et al., 2006, 2007).
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